limited-disease small-cell lung cancer
Conditions
Interventions
The CODE treatment phase consisted of 25 mg/m2 cisplatin (i.v.) once a week for 4 weeks, 45 mg/m2 doxorubicin (i.v.) on day 1, 80 mg/m2 etoposide (i.v.) on days 1 through 3 during weeks 1 and 3, and 1
Sponsors
West Japan Oncology Group
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: We included patients with cytologically or histologically proven small-cell lung cancer that had not undergone treatment. We defined LD as that confined to one hemithorax and any lymph nodes that could be covered by a single radiation therapy port. We included only patients with a good performance status, that is, an Eastern Cooperative Oncology Group scale value of 0 to 2. The test results as follows: white blood cell count ≥ 4,000/mm3, hemoglobin ≥ 11 g/dl, platelet count ≥ 100,000/mm3, total serum bilirubin ≤ 1.5 mg/dl, aspartate transaminase and alanine aminotransferase ≤ 100 IU/L, serum creatinine ≤ 1.2 mg/ml, 24 hour creatinine clearance ≥ 60 ml/min, and an arterial blood gas of oxygen of ≥ 70 mmHg. Disease stage was assessed by physical examination; chest radiography; computed tomography of the chest, brain, and abdomen; bone scintigraphy; bone marrow aspiration; and other tests as indicated. All patients gave informed consent for participation in this study.
Exclusion criteria
Exclusion criteria: The criteria were age ≥ to 18 years and ≤ 70years, no concurrent active malignancies.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoint was survival time and the secondary endpoints were the actual dose intensity, response rate, toxicity. | — |
Countries
Japan
Contacts
Public ContactTakeshi Isobe
Shimane University School of Medicine Department of Internal Medicine
Outcome results
None listed